Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2010 May 18;9(6):1596–1608. doi: 10.1158/1535-7163.MCT-09-1146

Figure 2. BITC causes decrease in HDAC1 and HDAC3 expression and activity level.

Figure 2

A, BxPC-3 cells were treated with different concentrations of BITC for 24h or treated with 10μM BITC for varying time intervals and the whole cell lysates were subjected to SDS-PAGE. Representative immunoblots show the effect of BITC treatment on the expression of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7 and HDAC8. Each blot was stripped and reprobed with anti-β-actin to ensure equal protein loading. Each experiment was repeated three times with similar results. B, HDAC1 and HDAC3 activity was determined in the nuclear lysates of DMSO and BITC treated BxPC-3 cells using HDAC Fluorescent Activity Assay kit. *Statistically different when compared with control, P < 0.05. C, Effect of SAHA was determined in BxPC-3 cells and compared with the effects of BITC. Cells were exposed to 0-100μM SAHA or BITC for 24h and evaluated for NF-kB, cyclin D1 and HDAC1/3 expression by western blotting and cell survival by SRB assay. D, BxPC-3 cells were treated with 0-20 μM BITC for 24h. Whole cell lysates were subjected to SDS-PAGE and the membranes were probed with p300/CBP, p21WAF1 and β-actin antibody. Each experiment was repeated three times with similar results.